BiotechTube
Lumiphore

Lumiphore

Berkeley, United States· Est.
lumiphore.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $200K

Overview

Lumiphore is a private, pre-clinical stage biotech firm leveraging its novel chelation platform to advance the field of radiotheranostics and diagnostics. Its core technology enables rapid, room-temperature labeling of a wide range of therapeutic and diagnostic radioisotopes, such as Lutetium and Zirconium, to targeting agents with high stability. The company is pursuing internal programs and partnerships to develop next-generation radiopharmaceuticals while also commercializing its lanthanide compounds for sensitive diagnostic assays. Lumiphore operates as an enabling technology provider, seeking collaborations with companies possessing novel targeting molecules.

Oncology

Technology Platform

Proprietary macrocyclic BiFunctional Chelate (mBFC) technology for room-temperature, stable labeling of therapeutic and diagnostic radiometals, and luminescent lanthanide compounds for high-sensitivity diagnostic assays.

Funding History

1
Total raised:$200K
Grant$200K

Opportunities

The rapid expansion of the targeted radiopharmaceutical and theranostics market, particularly in oncology, creates a high demand for superior chelation technology.
Lumiphore's versatile platform can enable multiple partners' programs, offering a scalable business model.
The growing need for highly sensitive diagnostic assays provides a parallel, near-term commercial pathway.

Risk Factors

The platform faces validation risk in human trials and competition from established chelators.
The company's progress is heavily dependent on securing strategic partnerships and sufficient funding.
Regulatory and manufacturing complexities for radiopharmaceuticals pose significant downstream challenges.

Competitive Landscape

Lumiphore competes in chelation technology with established players like Macrocyclics (Bicycle Therapeutics) and CheMatech, as well as academic and biotech innovators. In diagnostics, it competes with vendors of TR-FRET reagents like PerkinElmer and Cisbio. Its key differentiator is the combination of room-temperature labeling, exceptional stability, and broad metal versatility within a single platform.

More companies in Diagnostics & Precision Medicine →More companies in United States →